Cargando…

Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of the Congo

The Democratic Republic of the Congo (DRC) officially reports low coronavirus disease 19 (COVID-19) prevalence. This cross-sectional study, conducted between September and November 2021, assessed the COVID-19 seroprevalence in people attending Goma’s two largest markets, Kituku and Virunga. A simila...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitangala, Prudence Ndeba, Irenge, Leonid M., Musubao, Edgar Tsongo, Kahindo, Jean Bosco Mbeva, Ayonga, Patrick Ndeba, Kyembwa Safari, Israël, Kubuya, Janvier Bonane, Ntabe, Edmon Namegabe, Kabangwa Senga, Raphaël Kakongo, Mutombo, Guy Ndongala, Ambroise, Jérôme, Gala, Jean-Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600894/
https://www.ncbi.nlm.nih.gov/pubmed/37724000
http://dx.doi.org/10.1017/S0950268823001498
Descripción
Sumario:The Democratic Republic of the Congo (DRC) officially reports low coronavirus disease 19 (COVID-19) prevalence. This cross-sectional study, conducted between September and November 2021, assessed the COVID-19 seroprevalence in people attending Goma’s two largest markets, Kituku and Virunga. A similar study in a slum of Bukavu overlapped for 1 month using identical methods. COVID-19-unvaccinated participants (n = 796 including 454 vendors and 342 customers, 60% of whom were women) were surveyed. The median age of vendors and customers was 34.2 and 30.1 years, respectively. The crude and adjusted anti-SARS-CoV-2 antibody seroprevalence rates were 70.2% (95% CI 66.9–73.4%) and 98.8% (95% CI 94.1–100%), respectively, with no difference between vendors and customers. COVID-19 symptoms reported by survey participants in the previous 6 months were mild or absent in 58.9% and 41.1% of participants with anti-SARS-CoV-2 antibodies, respectively. No COVID-19-seropositive participants reported hospitalisation in the last 6 months. These findings are consistent with those reported in Bukavu. They confirm that SARS-CoV-2 spread without causing severe symptoms in densely populated settlements and markets and suggest that many COVID-19 cases went unreported. Based on these results, the relevance of an untargeted hypothetical vaccination programme in these communities should be questioned.